



4 July 2025

Sydney, Australia

## Notice of Change of Interests of Substantial Securityholder ("Notice")

**Nyrada Inc (ASX: NYR)**, a clinical stage drug discovery and development company specialising in innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depository Interests ("CDIs"), a Notice of Change of Interests of Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

**Name of Substantial Holder:** Mr Mark Azzi

**Date of change in the interests of the Substantial Holder:** 3 July 2025

**Previous and present voting power of Substantial Holder (through CHESSE Depository Nominees Pty Ltd):**

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
30,427,243	14.43%	32,583,494	15.45%

**Present Relevant Interests:**

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
Mr Mark Azzi	Mr Mark Azzi	32,183,494	15.26%
Mr Mark Azzi	Mr Mark Azzi	400,000	0.19%

(1) Based on 210,917,037 CDIs on issue as outlined in Appendix 3H released to ASX on 15 May 2025

For personal use only



NYR has provided a copy of this Notice to Mr Mark Azzi who has confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) (**Act**), including the number of equity securities or CDIs disclosed in the Notice, being 32,583,494 CDIs, and that these equity securities represent all equity securities held by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.

– ENDS –

### **About Nyrada Inc**

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr. James Bonnar, CEO on behalf of the Board.*

#### **Investor & Corporate Enquiries:**

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

#### **Company Secretary:**

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only